Pharmacogenetic Supported Prescribing in Kids
University of Calgary
6,000 participants
Jan 18, 2021
INTERVENTIONAL
Conditions
Summary
Implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.
Eligibility
Inclusion Criteria3
- Medical records available
- The initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated
- Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing
Exclusion Criteria3
- Medically unstable or lacking capacity to provided informed consent
- Unwillingness of child to provide saliva sample for genetic analysis
- History of liver or bone marrow (hematopoietic cell) transplant
Interventions
Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04797364